High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors

Proteasome inhibitors (PIs) are approved backbone treatments in multiple myeloma. More recently, inhibition of proteasome activity with the PI bortezomib has been clinically evaluated as a novel treatment strategy in pediatric acute lymphoblastic leukemia (ALL). However, we lack a marker that could...

Descripción completa

Detalles Bibliográficos
Autores principales: Besse, Lenka, Besse, Andrej, Kraus, Marianne, Maurits, Elmer, Overkleeft, Herman S., Bornhauser, Beat, Bourquin, Jean-Pierre, Driessen, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616377/
https://www.ncbi.nlm.nih.gov/pubmed/34831075
http://dx.doi.org/10.3390/cells10112853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616377/
https://www.ncbi.nlm.nih.gov/pubmed/34831075
http://dx.doi.org/10.3390/cells10112853

Ejemplares similares